rheumatoid arthritis

[International Immunopharmacology] Scientists modified the classical antigen-induced arthritis model by using citrullinated human plasma fibrinogen as an immunogen to investigate the mechanism of inflammation-driven joint damage by citrullinated human plasma fibrinogen (hFIB) in C57BL/6 mice.

[Scientific Reports] Researchers suggested that bone-resident osteoclasts and chondrocytes exerted mutually protective effects on their ‘native’ tissue. However, when osteoclasts contacted non-native cartilage, they caused degradation via matrix metalloproteinases (MMPs).

[Neurochemical Research] Investigators summarize the roles of different T cells and macrophages subsets in the occurrence and progression of rheumatoid arthritis (RA), and highlighted the immune consequences of cholinergic anti-inflammatory pathway activation in these cells under RA circumstances.

[GNS Healthcare] GNS Healthcare and Scipher Medicine announced plans to develop and launch Gemini— the in silico Patient™ for rheumatoid arthritis, to help patients reach target treatments sooner.

[Cell Reports] In three murine models, CD8+ cells bearing resident memory T cells markers remained in previously inflamed joints during remission.

[Trellis Rx (BusinessWire, Inc.)] Researchers announced the integration of PrismRA® into its clinical pathway for patients living with rheumatoid arthritis. Scipher Medicine, the manufacturer of PrismRA, is a precision immunology company helping providers determine the most effective therapy for their patients.